In late January this year, BioPharmaDispatch submitted a number of questions to the Department of Health in relation to processes regarding the pricing of MSD's KEYTRUDA (pembrolizumab) for lung cancer - its response dismissed the questions. …
Latest Video
New Stories
-
‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - - Latest News -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News -
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - - Latest News -
Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD
November 22, 2025 - - Australian Biotech -
Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes
November 22, 2025 - -
Alterity Therapeutics chairman reflects on two decades of progress as company enters new era
November 22, 2025 - - BioPharma -
Treasurer blocks US takeover of Mayne Pharma on national interest grounds
November 22, 2025 - - Latest News